293 related articles for article (PubMed ID: 37477229)
1. A two-decade journey in identifying high mobility group box 1 (HMGB1) and procathepsin L (pCTS-L) as potential therapeutic targets for sepsis.
Li J; Zhu CS; He L; Qiang X; Chen W; Wang H
Expert Opin Ther Targets; 2023; 27(7):575-591. PubMed ID: 37477229
[TBL] [Abstract][Full Text] [Related]
2. Endogenous Regulation and Pharmacological Modulation of Sepsis-Induced HMGB1 Release and Action: An Updated Review.
Zhu CS; Wang W; Qiang X; Chen W; Lan X; Li J; Wang H
Cells; 2021 Aug; 10(9):. PubMed ID: 34571869
[TBL] [Abstract][Full Text] [Related]
3. Targeting HMGB1 in the treatment of sepsis.
Wang H; Ward MF; Sama AE
Expert Opin Ther Targets; 2014 Mar; 18(3):257-68. PubMed ID: 24392842
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of HMGB1-targeting agents in sepsis.
Wang H; Zhu S; Zhou R; Li W; Sama AE
Expert Rev Mol Med; 2008 Nov; 10():e32. PubMed ID: 18980707
[TBL] [Abstract][Full Text] [Related]
5. Development of Procathepsin L (pCTS-L)-Inhibiting Lanosterol-Carrying Liposome Nanoparticles to Treat Lethal Sepsis.
Chen W; Zhu CS; Qiang X; Chen S; Li J; Wang P; Tracey KJ; Wang H
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239992
[TBL] [Abstract][Full Text] [Related]
6. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.
Wang H; Ward MF; Sama AE
Shock; 2009 Oct; 32(4):348-57. PubMed ID: 19333143
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic potential of procathepsin L-inhibiting and progesterone-entrapping dimethyl-β-cyclodextrin nanoparticles in treating experimental sepsis.
Qiang X; Chen W; Zhu CS; Li J; Qi T; Lou L; Wang P; Tracey KJ; Wang H
Front Immunol; 2024; 15():1368448. PubMed ID: 38550581
[TBL] [Abstract][Full Text] [Related]
8. Identification of procathepsin L (pCTS-L)-neutralizing monoclonal antibodies to treat potentially lethal sepsis.
Zhu CS; Qiang X; Chen W; Li J; Lan X; Yang H; Gong J; Becker L; Wang P; Tracey KJ; Wang H
Sci Adv; 2023 Feb; 9(5):eadf4313. PubMed ID: 36735789
[TBL] [Abstract][Full Text] [Related]
9. An ongoing search for potential targets and therapies for lethal sepsis.
Bao GQ; He L; Lee D; D'Angelo J; Wang HC
Mil Med Res; 2015; 2():20. PubMed ID: 26257917
[TBL] [Abstract][Full Text] [Related]
10. The role of high mobility group box 1 in innate immunity.
Lee SA; Kwak MS; Kim S; Shin JS
Yonsei Med J; 2014 Sep; 55(5):1165-76. PubMed ID: 25048472
[TBL] [Abstract][Full Text] [Related]
11. Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury.
Deng C; Zhao L; Yang Z; Shang JJ; Wang CY; Shen MZ; Jiang S; Li T; Di WC; Chen Y; Li H; Cheng YD; Yang Y
Acta Pharmacol Sin; 2022 Mar; 43(3):520-528. PubMed ID: 34040166
[TBL] [Abstract][Full Text] [Related]
12. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1.
Li W; Li J; Ashok M; Wu R; Chen D; Yang L; Yang H; Tracey KJ; Wang P; Sama AE; Wang H
J Immunol; 2007 Mar; 178(6):3856-64. PubMed ID: 17339485
[TBL] [Abstract][Full Text] [Related]
13. HMGB1 as a potential therapeutic target.
Wang H; Li W; Goldstein R; Tracey KJ; Sama AE
Novartis Found Symp; 2007; 280():73-85; discussion 85-91, 160-4. PubMed ID: 17380789
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.
Chorny A; Delgado M
Am J Pathol; 2008 May; 172(5):1297-307. PubMed ID: 18385521
[TBL] [Abstract][Full Text] [Related]
15. Targeting high mobility group box 1 as a late-acting mediator of inflammation.
Czura CJ; Tracey KJ
Crit Care Med; 2003 Jan; 31(1 Suppl):S46-50. PubMed ID: 12544976
[TBL] [Abstract][Full Text] [Related]
16. The Regulatory Role of High-Mobility Group Protein 1 in Sepsis-Related Immunity.
Li L; Lu YQ
Front Immunol; 2020; 11():601815. PubMed ID: 33552058
[TBL] [Abstract][Full Text] [Related]
17. Glycyrrhizin attenuates caspase-11-dependent immune responses and coagulopathy by targeting high mobility group box 1.
Wang Z; Yang X; Wang X; Liang F; Tang Y
Int Immunopharmacol; 2022 Jun; 107():108713. PubMed ID: 35339905
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory response and immune regulation of high mobility group box-1 protein in treatment of sepsis.
Liu QY; Yao YM
World J Emerg Med; 2010; 1(2):93-8. PubMed ID: 25214948
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of high-mobility group box 1 as therapeutic option in autoimmune disease: lessons from animal models.
Schaper F; Heeringa P; Bijl M; Westra J
Curr Opin Rheumatol; 2013 Mar; 25(2):254-9. PubMed ID: 23249831
[TBL] [Abstract][Full Text] [Related]
20. High-mobility group box-1 isoforms as potential therapeutic targets in sepsis.
Parrish W; Ulloa L
Methods Mol Biol; 2007; 361():145-62. PubMed ID: 17172710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
